Heart malignant hemangiopericytoma

Summary

Heart malignant hemangiopericytoma (MONDO:0003743) is a disease. A subtype of hemangiopericytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	heart malignant hemangiopericytoma
Mondo ID	MONDO:0003743
DOID	DOID:6034
NCIT	C5365
UMLS	C1334567
MedGen	233144
GARD	0027645
Anatomy (UBERON)	UBERON:0000948
Is cancer (heuristic)	no

Also known as: heart hemangiopericytoma · heart spindle cell tumor · heart spindle cell tumour · malignant Cardiac hemangiopericytoma · malignant heart hemangiopericytoma · malignant hemangiopericytoma of heart · malignant hemangiopericytoma of the heart

Disease family

This is a subtype of hemangiopericytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › pericytic neoplasm › hemangiopericytic tumor › hemangiopericytoma › heart malignant hemangiopericytoma

Related subtypes (7): kidney hemangiopericytoma, meninges hemangiopericytoma, breast hemangiopericytoma, retroperitoneal hemangiopericytoma, adult intracranial malignant hemangiopericytoma, hemangiopericytoma, malignant, hemangiopericytoma of skin

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.